Nuclear Processes and Cytokine Synthesis
T-lymphocyte activation begins with profound intracellular changes. The key event at this stage is the translocation of the active transcription factor NFAT. Importantly, it translocates directly into the cell nucleus (bypassing the cytoplasm, Golgi apparatus, or endoplasmic reticulum).
Once inside the nucleus, NFAT initiates gene expression, primarily the transcription of the interleukin-2 gene (IL-2 gene). This process produces IL-2 messenger RNA (mRNA). The presence of mRNA serves as a direct instruction for the cellular machinery, leading to active synthesis and subsequent secretion of interleukin-2 protein into the extracellular space.
Pharmacological target: Glucocorticoids act at this initial stage. Their mechanism of action involves potent suppression of IL-2 gene expression and blockade of proinflammatory cytokine synthesis directly at the nuclear level, stopping the immune response at its very onset.
Autocrine and Paracrine Stimulation
Once interleukin-2 is secreted into the extracellular space, it acts as a potent catalyst for downstream reactions. Secreted IL-2 binds to a specific IL-2 receptor located on the surface of the T-lymphocyte itself. Notably, interaction occurs specifically with this receptor rather than with TNF-α, IL-1, or IL-4 receptors.
This binding provides autocrine (effects on the cell itself) or paracrine (effects on neighboring cells) stimulation, significantly amplifying the signal for cell division.
Pharmacological target: Daclizumab is used to interrupt this stimulation loop. This monoclonal antibody specifically blocks the IL-2 receptor. By occupying the receptor, the drug renders the cell completely unresponsive to stimulation by this cytokine.
Proliferation Signaling Pathway (mTOR)
Successful activation of the IL-2 receptor immediately triggers signal transduction into the cell. The primary conductor here is the intracellular kinase pathway mTOR (mammalian target of rapamycin). In this context, mTOR is specifically activated rather than alternative cascades such as MAPK/ERK, NF-κB, or JAK-STAT.
The function of the mTOR pathway is critical for cell cycle control. This enzyme acts as a molecular switch that ensures the transition of the T-lymphocyte from the resting and initial growth phase ($G_1$) to the active DNA synthesis phase ($S$). Without this transition, cell division is physically impossible.
Pharmacological target: This signaling pathway is the point of action for sirolimus. The drug specifically inhibits mTOR, leading to an immediate cell cycle arrest and preventing further T-lymphocyte division.
Final Proliferation and Differentiation
If all checkpoints are passed and the cell cycle is successfully completed, the final stage occurs. Completion of the cycle leads to clonal proliferation (mass replication) and differentiation of T-lymphocytes. The cell proceeds specifically down the path of replication, avoiding outcomes such as apoptosis, chemotaxis, or anergy.
Pharmacological target: During the phase of direct cell division, drugs with cytostatic action—azathioprine and mycophenolate—come into play. Their function is to inhibit purine and DNA synthesis. Because creating each new cell requires duplication of genetic material, inhibiting purine synthesis effectively blocks proliferation.